Priority review for Novartis CAR-T cell therapy Kymriah
Novartis is eyeing approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma - News - PharmaTimes
Source: pharmatimes.com
Page 9 - Hematology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematology Development Today - Breaking & Trending Today
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia
Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the first data from the Phase 2 BEYOND study evaluating Reblozyl ...
Source: investingnews.com
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia (AML) sub...
Source: investingnews.com